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Trichomonas vaginalis (trichomoniasis) is a parasite of the urogenital area.(1) Trichomoniasis is 
not a notifiable infection in most countries and, as the majority of infections remain asymptomatic, 
there is lack of epidemiological data for the infection. In the USA and the UK, screening of 
trichomoniasis among asymptomatic individuals in the general population is not recommended 
by the guidelines.(2, 3)  In Australia, opportunistic testing for asymptomatic trichomoniasis is done 
during cervical screening appointments using Pap smear test and wet mount microscopy, which 
has a sensitivity around 50-60% for trichomoniasis detection.  New guidelines were introduced in 
2017 to replace cytology-based testing with PCR testing for high-risk (HR) HPV infection, such 
that cervical cytology is only conducted for those who test positive for HR-HPV.(4) 
 
In this issue, Hui et al.(5) have used mathematical modeling to estimate potential indirect effects 
of the cervical screening guideline changes on trichomoniasis prevalence in Australia. In the 
study, a deterministic compartmental model of trichomoniasis transmission among heterosexual 
population was calibrated to low level (0.4%) trichomoniasis prevalence reflecting urban 
Australian population, and assuming a steady age-specific cytology-based cervical cancer 
screening rate among women over 18 years. The authors compare the prevalence in the 
calibrated model to future estimates of trichomoniasis population prevalence in presence of 
reduced frequency of Pap smear tests. The study suggests that introducing HR-HPV testing could 
  
lead to a substantial increase in trichomoniasis prevalence in the urban population in Australia 
over a twenty-year period.  
 
Mathematical modelling is a useful analytical tool,(6) which offers a relatively rapid, low cost and 
low risk method to predict the impact of existing and novel interventions. Models can lead to 
improved understanding of the ways in which infectious diseases interact, and reveal indirect and 
unintended consequences of interventions. This provides valuable hypotheses for further 
epidemiological research, which is one of the major contributions of the study by Hui et al. There 
are few transmission models of trichomoniasis,(7, 8) and the study presented in this issue 
examines a complex research question in the intersection of two sexually transmitted infections 
(STI). 
 
Where data are scarce, we need to set appropriate expectations to what mathematical modeling 
can do. With rich data, a model can be calibrated to multiple data sources, validated, and then 
used for forecasting, whilst propagating parameter uncertainty. In the absence of such data 
resources, a modeling study remains at hypotheses generating phase. In their study, Hui et al. 
focused on the indirect effects of cervical cancer screening implementation on trichomoniasis 
detection. Table 1 describes the broader context of potential interactions between HR-HPV and 
trichomoniasis, and provides suggestions for future modeling work for trichomoniasis.  A key 
determinant of STI acquisition risk is differences in (unprotected) sexual activity within the 
population, with higher number of partners being associated with both HR-HPV and 
trichomoniasis acquisition. In the trichomoniasis model, the transmission dynamics of HR-HPV 
were not included in the model framework, and the prevalence of trichomoniasis among those 
who had HR-HPV infection was assumed to be the same as in the general population. Given the 
same mode of transmission, we might expect there to be a higher prevalence of trichomoniasis 
among those infected with HR-HPV than those not infected with HR-HPV, and this in turn may 
  
result in larger number of trichomoniasis being detected under new guidelines than estimated in 
the study. Assumptions of the intensity of control strategies at baseline, prior to comparison to 
counterfactuals, will also impact the magnitude of change seen in the counterfactuals.(9)   
 
We may also consider variation within the population; increasing heterogeneity in STI distribution 
in the population makes it easier to sustain a stable, low population prevalence of infection, but it 
will make the infection harder to control due to subgroups of the population being exposed to the 
pathogen at higher rate than others.(6) If heterogeneities are epidemiologically important in a 
given setting, and they have not been included in the model framework, the model estimates of 
intervention impact can be overestimated. Trichomoniasis prevalence is marked by variation 
regionally and among minority populations. Trichomoniasis positivity is estimated as 0.4% in 
Sydney,(10) whilst positivity is 8.4-25% in rural areas and higher among Aboriginal 
populations.(11, 12) Trichomoniasis is also associated with older age.(13) 
 
In order to  take this variation into account in trichomoniasis modeling, we need further data on 
number of trichomoniasis infections diagnosed in different settings, and how these are changing 
over time. As an example, the model was calibrated to a single clinic-based positivity estimate of 
trichomoniasis.(10) There are other plausible scenarios that could have given rise to a good model 
fit, but that would have resulted in lower contribution of cervical cytology to trichomoniasis control.  
Furthermore, data are urgently needed now that the field is moving towards point of care testing 
amid considerations of wider implementation of trichomoniasis testing.(14) It is challenging to limit 
the scope of a modeling study to what is feasible, and supported by data. Prior assumptions are 
also required to create any modeling framework, and the study by Hui et al. brings about 
interesting questions to explore in the future.  
 
  
Table 1. Conceptualizing how proximate and distal factors for trichomoniasis (TV) can create 
interactions with HR-HPV and further heterogeneity at the population level  
 
 Proximate and distal factors contributing to  HR-HPV and TV epidemiology 
 Natural history of 
Trichomoniasis 
Sexual risk behavior 
 
More distal sources of 
heterogeneity (age, 
ethnicity, urbanicity, 
region) 
HR-HPV 
epidemiology, 
and cervical 
screening 
interventions 
It is unclear how many TV 
cases are detected via 
cervical cytology.  Whether 
there are biological 
interactions between HR-
HPV and TV is not known. 
Individuals with more sexual 
partners are more likely to have 
HR-HPV. They may also have 
different test-seeking behaviors. 
Variation in cervical screening 
and vaccine uptake in the 
population.  
Trichomoniasis 
(TV)  
epidemiology 
There are a number of 
uncertainties around the 
natural history and infection 
duration for TV among 
women and men. 
Individuals with more sexual 
partners are more likely to have TV. 
There is marked variation in 
TV prevalence in the 
population, and higher 
prevalence of TV among 
older populations. 
Future 
considerations 
for modeling TV 
Sensitivity analyses similar 
to those done by Hui et al. 
offer a way to explore the 
uncertainty around natural 
history parameters.  
 
Time series data are 
needed for TV testing and 
diagnoses in different 
settings to improve model 
estimates. 
 
Impact and cost-
effectiveness of testing 
asymptomatic people for TV 
is not known. 
Individuals with HR-HPV infection 
are more likely to be infected with 
TV, resulting in greater co-infection 
prevalence than if the infections 
were independently distributed.  
Future modeling studies should 
account for this if they examine the 
impact of cervical screening 
interventions. 
 
 
Findings from a model 
calibrated to one setting may 
not be applicable to other 
settings in presence of 
different epidemiological 
characteristics.  
Unexplored heterogeneities 
may also overestimate the 
impact of interventions. 
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